GH56 Monotherapy for Second-line Treatment of MTAP-Deleted ESCC
A Multicenter, Open-Label Study to Evaluate Efficacy and Safety of GH56 Monotherapy for Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With MTAP Deficiency
This is a Phase 2/3, open-label, multicenter study to evaluate the efficacy and safety of GH56 as a single agent in participants with advanced Esophageal Squamous Cell Carcinoma(ESCC) with methylthioadenosine phosphorylase (MTAP) deficiency in the second-line or later setting. In this seamlessly designed Phase 2/3 study, a single-arm Phase 2 study will be conducted first, and after favorable efficacy data are obtained, a Phase 3 study comparing against standard chemotherapy will then be conducted.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Bo Ning, Master
- 電話番号:+86-0512-86861608
- メール:ningbo@genhousebio.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed written informed consent, voluntarily participating in this study.
- Age ≥ 18 years, male or female.
- Patients with histopathologically or cytologically confirmed esophageal squamous cell carcinoma who cannot be treated surgically and have failed 1L standard of care (SoC) .
- MTAP deficiency is confirmed by IHC or NGS .
- At least one measurable lesion as per RECIST v1.1 criteria.
- ECOG performance status of 0 or 1.
- Life expectancy > 3 months.
- Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory.
- Has a negative serum pregnancy test result at screening and is able to comply with contraceptive-barrier requirements.
Exclusion Criteria:
- Previous anti-tumor treatments did not meet the elution deadline requirements specified in the protocol; .
- Known or suspected that there is an allergy to GH56 active ingredients and/or GH56 capsule excipients;
- Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
- Tumor invasion of the central nervous system, large blood vessels, trachea, serosal cavity, and other areas may have a significant impact on the compliance, safety, and efficacy evaluation of this trial .
- Patients cannot take oral medication or has severe absorption disorders .
- Unresolved toxicity from prior anti-cancer therapy.
- Patients with uncontrolled clinical symptoms or disease such as other malignant tumors, cardiovascular and cerebrovascular diseases, nervous/mental diseases, respiratory diseases, digestive diseases, immune and infectious diseases.
- Active infection of HIV, HBV, syphilis or HCV .
- Conditions that the investigator considers inappropriate for participation in this clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:GH56 Capsule Group
GH56 RP2D administered to patients with MTAP-Deleted ESCC |
Planned dose administered on specified days per protocol |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:Approximately 2 years
|
The percentage of participants having complete response (CR) or partial response (PR) assessed based on RECIST V1.1 |
Approximately 2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:Approximately 2 years
|
Progression-Free Survival assessed by investigators based RECIST v1.1 |
Approximately 2 years
|
|
Overall Survival (OS)
時間枠:Approximately 2 years
|
Overall Survival after first dose |
Approximately 2 years
|
|
Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)
時間枠:Approximately 2 years
|
Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs |
Approximately 2 years
|
|
Pharmacokinetic characteristics of GH56
時間枠:Approximately 2 years
|
Plasma Concentration of GH56 |
Approximately 2 years
|
協力者と研究者
捜査官
- 主任研究者:bo Zheng Song, Doctorate、Zhejiang Cancer Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- GH56C204
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。